Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer

Mototsugu Shimokawa, Takahiro Kogawa, Takako Shimada, Toshiaki Saito, Hozumi Kumagai, Masafumi Ohki, Tsunehisa Kaku

研究成果: Contribution to journalArticle査読

9 被引用数 (Scopus)

フィンガープリント

「Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Medicine & Life Sciences